Answers are grounded in this paper and cite their sources.
) moiety as a side chain to the Valine-Lysine-PAB (VK) linker, demonstrated maximum hydrophilicity, biophysical stability, and tumor suppression, along with prolonged half-life and enhanced animal tolerability. In conclusion, through PEGylation of the traditional dipeptide linker, we have demonstrated an optimized ADC conjugation technology that can be employed for conjugating ultrahydrophobic payloads, thus enhancing both the therapeutic index and pharmacokinetics profile.
No takes yet. Share an insight, caveat, or question.
Long et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: